

FIG. 1 : shows cross-sectional (side) view and area (top) view of a monolithic matrix film




FIG. 2: shows cross-sectional (side) view and area (top) view of a micro-deposited matrix film




FIG. 3: Diffusion of Dexmedetomidine in Formulations 1 to 7 and Formulation 11 and Precedex® through oral cell culture membrane




FIG. 4: Mean Dexmedetomidine Plasma Log Concentration vs. Time for Dose Levels 10, 20 and 40 mcg Dexmedetomidine Sublingual Film—Semi-log Scale




FIG 5A. Individual Dexmedetomidine Concentration-time Profiles for all Subjects by dose after administration of Dexmedetomidine sublingual film (10 mcg) Semi-log Scale




FIG 5B: Individual Dexmedetomidine Concentration-time Profiles for all Subjects by dose after administration of Dexmedetomidine sublingual film (20 mcg) Semi-log Scale




FIG 5C: Individual Dexmedetomidine Concentration-time Profiles for all Subjects by dose after administration of Dexmedetomidine sublingual film (40 mcg) Semi-log Scale




FIG 6: Mean VAS/S score vs. Nominal Time after administration of Dexmedetomidine sublingual film (10, 20, 40 mcg) and Placebo




FIG 7. Standing Systolic BP vs Nominal Time after administration of Dexmedetomidine sublingual film (10, 20, 40 mcg) and Placebo




FIG 8: Supine Systolic BP, vs Nominal Time after administration of Dexmedetomidine sublingual film 10 mcg, 20 mcg and 40 mcg and Placebo




FIG 9: Standing Diastolic BP vs Nominal Time after administration of Dexmedetomidine sublingual film 10 mcg, 20 mcg and 40 mcg and Placebo




FIG 10: Supine Diastolic BP vs Nominal Time after administration of Dexmedetomidine sublingual film 10 mcg, 20 mcg and 40 mcg and Placebo




FIG 11: Pulse Rate vs Nominal Time after administration of Dexmedetomidine sublingual film 10 mcg, 20 mcg and 40 mcg and Placebo




FIG. 12: depicts the percentage of schizophrenic patients achieving RASS -1 in the treatment arm (IV dexmedetomidine hydrochloride treated group) versus placebo group




FIG. 13: depicts mean drop in PEC score in schizophrenic patients in the treatment arm (IV dexmedetomidine hydrochloride treated group) versus placebo group




FIG. 14: depicts the maximum doses of IV dexmedetomidine hydrochloride received by schizophrenic patients for the treatment of agitation




FIG. 15: depicts the total intravenous dose of IV dexmedetomidine hydrochloride received by schizophrenic patients for the treatment of agitation




FIG 16: Mean Plasma concentration (pg/ml) vs actual time. Plasma concentration mean values in schizophrenic patients treated with IV dexmedetomidine hydrochloride - Semi-log scale




FIG. 17. Mean ($\pm$ SD) Dexmedetomidine Plasma Concentration-Time, sorted by Dose Level (Linear Scale)




FIG. 18: Mean ($\pm$ SD) Dexmedetomidine Plasma Concentration-Time, sorted by Dose Level (Semi-log Scale)




FIG 19: Mean ($\pm$ SD) Change in PEC Score from Baseline, (Cohort 3; dose 120 mcg, no redose)




FIG 20: Mean ($\pm$ SD) Percent Change in PEC Score from Baseline. (Cohort 3, dose 120 mcg, no redose)

